logo
Elite Rowers Face Lasting Atrial Fibrillation Risk

Elite Rowers Face Lasting Atrial Fibrillation Risk

Medscape03-07-2025
Former world-class rowers have an elevated risk for atrial fibrillation (AF) in the years after retirement, according to an observational case-control study.
Researchers found 1 in 5 former Olympic, world, or national-level Australian rowers aged 45-80 years had the heart rhythm anomaly. The ex-rowers, who had competed for at least 10 years, were nearly seven times more likely to have been diagnosed with AF compared to a control group. During a follow-up period of around 4 years, new cases of AF were also higher among the ex-rowers (6.3% vs 2.3%), according to the researchers, who published their findings last month in the European Heart Journal .
'As a clinician, I was not surprised that rowers experienced more AF,' said André La Gerche, PhD, MD, a cardiologist and head of the Heart Exercise And Research Trials Lab at the Victor Chang Cardiac Research Institute and St Vincent's Hospital in Melbourne, Australia, and senior author of the study. 'However, I was very surprised by the magnitude of the difference. Furthermore, I learnt that the risk persists years after retirement and is not just due to genetic factors.'
André La Gerche, PhD, MD
The findings are 'consistent with prior research demonstrating that endurance athletes — especially highly trained endurance athletes — seem to have this higher risk of AF,' said Gregory Marcus, MD, MAS, a cardiac electrophysiologist and the inaugural Endowed Professor of Atrial Fibrillation Research at the University of California, San Francisco.
Gregory Marcus, MD, MAS
'These numbers nudge me in the direction of more aggressively screening for AF specifically in masters-aged rowers, such as with the use of Holter monitors or wearable devices approved to detect AF,' said Jeffrey Hsu, MD, an assistant professor of medicine in the Division of Cardiology at the David Geffen School of Medicine at the University of California, Los Angeles.
Jeffrey Hsu, MD
La Gerche and his team captured data from 121 former rowers — 75% men, all White, with a median age of 62 years — who were matched with more than 11,000 control individuals from the UK Biobank who had never rowed and had varying fitness levels. The ex-rowers had similar rates of ischemic heart disease and diabetes as did the control individuals, but lower blood pressure. They also were less likely to have ever smoked.
The athletes showed persistent changes in cardiac function after retirement. Ex-rowers had larger left ventricles, lower heart rates, longer PQ intervals, and longer QT intervals compared to control individuals.
The research, 'raises the question of whether certain types of intensive exercise — like elite-level competitive rowing — leads to long-lasting, perhaps even irreversible, enlargement of the cardiac chambers,' Hsu said.
Genetics factored into the risk for AF among both groups. While the prevalence of rare variants in genes associated with cardiomyopathy was low across the study, the combined risk for individual genes associated with AF was a strong predictor of the disease in both athletes (odds ratio [OR], 3.7) and nonathletes (OR, 2.0). The proportions were similar between them ( P = .37), indicating genetics did not fully account for the increased risk in the ex-rowers, La Gerche said.
Marcus flagged a few factors that may have skewed the results. The former athletes tended to be tall, White, and in many cases, drank more alcohol than control individuals — all of these factors increase the risk for AF.
Because the ex-rowers volunteered for a cardiovascular study, selection bias could have skewed prevalence higher, Marcus said. After a sensitivity analysis, ex-rowers still had a 2.5-fold higher risk for AF in the case of a 100% selection bias.
La Gerche emphasized the findings shouldn't dissuade clinicians from encouraging regular exercise or high-level sports training.
'The overall health outcomes of these rowers are generally superb,' La Gerche said. 'Rather, this highlights an important 'Achilles heel' that requires attention and, ideally, effective prevention strategies so that sports can be enjoyed by more people, more often.'
The study was funded by the National Health and Medical Research Council. La Gerche, Hsu, and Marcus reported having no relevant financial conflicts of interest.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Matching Occupational Exoskeletons With The Right Work Task
Matching Occupational Exoskeletons With The Right Work Task

Forbes

timean hour ago

  • Forbes

Matching Occupational Exoskeletons With The Right Work Task

Regardless of whether one thinks of industrial exoskeletons as personal protective equipment (PPE), an engineering solution, or something in between, these wearable devices are still an ergonomic solution that needs to be applied to the correct problem. In the decade that this technology has started to see an ever-growing adoption at work sites, the responsibility of matching the exoskeleton with a job task continues to fall on the end user or buyer. This is a persistent hurdle towards mass adoption, with several solutions on the horizon. How it started: Like any new technology, exoskeleton startups had no choice but to sell their products directly. This meant that if a company wanted to select and compare devices, it had to discover each one and establish unique communication channels. This process can be slow and laborious, and the lessons learned by one buyer are often not shared with others. One exception that exists in the public domain is 'The implementation of cobotics and exoskeletal devices for the Australia red meat processing industry,' a 91-page report published by AMPC comparing 19 industrial exoskeletons. Ten years later, the landscape has gone through some dramatic changes. Multiple standards bodies have looked into classifying and evaluating occupational exoskeletons. Fraunhofer IPA, a leading German research institute, has created a series of parcours to evaluate occupational exoskeletons as product families grouping results by task. Another change is the emergence of distributors, which could either be dedicated to one supplier or carry multiple products from different developers. As a quick note, choosing the correct exoskeleton solution (or deciding if a wearable is even the correct solution) for a repetitive work task is just one piece of the puzzle for a successful implementation. Still, it is often the first step in the process, and an error there will cascade down through pilots and long-term adoption efforts (and will most certainly negatively impact any return business). Even with all these changes, the majority of occupational exoskeletons are still sold directly by their producers, with some alternative acquisition and comparison pathways emerging: First, several dedicated consulting companies have sprouted in North America and Europe, which can provide support in choosing the right exoskeleton system for a fee. Second, some distributors carry devices from multiple developers, and their sales team is becoming more experienced with the strengths of each one. Third, some companies go beyond the role of a distributor and have become closer to an integrator that goes on a journey with the end user and buyers, helping them through the entire process of selection, comparison, and setting up a pilot. Last but not least, in the age of AI and digital tools, there have been multiple systems proposed that can collect data from repetitive work tasks, and some are designed specifically for wearables. The challenge with this digital solution is data collection, which can range from cell phone videos to motion tracking or even full EMG studies, but that is not all, because in addition to data collection, data interpretation with these systems is not trivial and requires effort before it can be condensed and summarized into a digestible report. How could things shape up in the future? There are a few likely scenarios on how the complexity of selecting an occupational exoskeleton could be reduced while creating a more positive and streamlined experience for decision makers and buyers. The car dealership route - developers of occupational exoskeletons could continue to consolidate so that each one has a full portfolio. This would be similar to shopping for a car, where car company A would offer sedans through trucks and everything in between, and the dealership next to it would offer the same range of vehicle classes from a different maker. An alternative to that would be an increase in multi-vendor distributors that already carry competing brands. Some examples of this happening right now would be Stanley Handling and FoxInnovation in Europe, The Exoskeleton Store and ExxoVantage in the Americas and Oceania. With this model, buyers have to visit fewer places and can also leverage the experience of the multi-vendor distributors to assist with selection. The final version could be an investment and improvement in digital tools. This could include online comparison tools, such as those found on car or camera equipment websites, or something more custom that can collect and interpret data from job sites and compare it against the known capabilities of different types and brands of industrial exoskeletons. All this work will lead to the formation of a marketplace, allowing buyers and end users to compare and evaluate industrial wearable solutions against data or prior knowledge. This would simplify the buying process considerably and lower the entry barrier for professionals and companies interested in becoming early adopters of wearable devices that provide direct physical support for their jobs.

VB Spine Launches in Australia and New Zealand
VB Spine Launches in Australia and New Zealand

Yahoo

time2 hours ago

  • Yahoo

VB Spine Launches in Australia and New Zealand

Stryker's spinal implants business in Australia and New Zealand fully transitions to VB Spine and LifeHealthcare continues as exclusive distributor NEW YORK & SYDNEY, July 31, 2025--(BUSINESS WIRE)--VB Spine LLC ("VB Spine"), a global, family-led spine company dedicated to advancing patient outcomes, announced the completion of the sale of Stryker's spinal implants business in Australia and New Zealand. This milestone builds upon the formation of VB Spine on April 1, 2025, following the acquisition of Stryker's U.S. spinal implants business by Viscogliosi Brothers, LLC. It also marks VB Spine's first market entry outside the United States and establishes a direct presence in two fast-growing markets. VB Spine continues to have exclusive access to Stryker's Mako Spine and the Copilot automatic depth stop feature. This strategic partnership creates a strong foundation for VB Spine's continued growth, providing surgeons greater precision and improving patient outcomes. "From the start, our vision has been simple: put patients first and innovate boldly," said Marc Viscogliosi, co-CEO of VB Spine, speaking for his brothers and fellow co-CEOs Anthony and John Viscogliosi. "Today we take that vision global. By combining the passion of our family-run culture with LifeHealthcare's best-in-class surgeon support, we're opening a new chapter in spine care defined by access, outcomes, and possibility." LifeHealthcare, already the long-standing distributor for these products, will continue as the exclusive partner, providing uninterrupted product availability and clinical support for surgeons and their patients throughout Australia and New Zealand. Paul Petherbridge, CEO of LifeHealthcare, said, "We are pleased to announce our long-term collaboration with VB Spine. LifeHealthcare has represented this portfolio since 2010, providing clinicians and patients in Australia and New Zealand with reliable access to spinal instrumentation and implants through our experienced team. Our partnership with VB Spine aligns with our mission for Spine in ANZ: 'What matters to you drives us.' We look forward to working with the Viscogliosi brothers and the VB Spine team to offer innovative solutions and valuable education to our clinicians." Transition highlights All current spinal implant SKUs remain available through LifeHealthcare with no service interruption. Surgeons and hospitals will continue to work with their local LifeHealthcare representatives. VB Spine plans to attend Deformity Down Under (DDU) in Brisbane, which began as a surgeon-led initiative to foster collaboration, share knowledge, and improve outcomes in spine surgery. Forward-looking statements Certain statements in this release are forward-looking and are based on current expectations, forecasts, and assumptions. Actual results may differ materially due to regulatory, commercial, and operational risks. VB Spine disclaims any obligation to update forward-looking statements except as required by law. Transaction financing Viscogliosi Brothers, LLC and Viscogliosi Brothers Watermark Holdings LLC are equity investors in VB Spine. About VB Spine VB Spine LLC is the largest privately held spine company and among the largest family-owned medical technology companies in the world. With a comprehensive product portfolio and a large and growing global distribution network, VB Spine delivers specialized solutions that address critical needs in spine surgery and enhance patient outcomes. Focused on people, partnerships and operational excellence, VB Spine ensures healthcare professionals have access to the tools and resources needed to provide the highest standard of care. VB Spine is owned and led by the Viscogliosi Brothers. For more information on VB Spine, please visit About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at About LifeHealthcare Distribution Pty Ltd (Australia) and LifeHealthcare Ltd (New Zealand) LifeHealthcare, an EBOS MedTech company, is committed to providing patients in Australia and New Zealand with access to world-class medical devices and technology. Our goal is to ensure the long-term economic sustainability of the healthcare system. We offer a diverse range of products across various channels for surgical intervention, including but not limited to therapeutic areas such as Spine and Enabling Technology, Orthopaedics (Reconstruction, Extremities, and Regenerative Medicine), Plastics and Reconstructive Surgery, Neurovascular Intervention, Abdo-Pelvic Surgery, and Neurosurgery, among others. For more information about LifeHealthcare, please visit or About Viscogliosi Brothers Viscogliosi Brothers, LLC is a family-owned New York City-based family office dedicated to driving growth and innovation in the neuro-musculoskeletal industry. Established in 1999, the firm focuses on identifying and building groundbreaking innovations in healthcare, aiming to address unmet clinical needs, enhance patient outcomes, and drive cost efficiency in the healthcare system. Since its inception 26 years ago, Viscogliosi Brothers has founded, financed, operated and grown 43 businesses with operations and distribution across more than 80 countries. These businesses have positively impacted millions of patients with cutting-edge innovations in healthcare. The firm has led the transformation of the spine industry through its multiple businesses specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma and Woven Orthopedic Technologies, among others. For more information, visit About Viscogliosi Brothers Watermark Viscogliosi Brothers Watermark LLC is a New York City-based holding company specializing in investing in innovation within the MedTech sector. Founded in 2022, VBW is committed to creating alternative wealth for its shareholders while enhancing humanity's well-being. With a portfolio-driven investment mandate and strategic expertise, VBW supports its invested entities through financing and manufacturing capabilities. For more information, visit View source version on Contacts For media inquiries only: vbspinecommunications@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Horrifyingly Huge New Stick Insect Discovered Exactly Where You Think
Horrifyingly Huge New Stick Insect Discovered Exactly Where You Think

Gizmodo

time2 hours ago

  • Gizmodo

Horrifyingly Huge New Stick Insect Discovered Exactly Where You Think

Australia is famous for hosting the weirdest creatures we've ever seen. Sometimes, these weird creatures also come extra-large—like the newly discovered stick insect that researchers believe may be the heaviest of all Aussie insects. The insect, named Acrohylla alta, is about 15 inches (40 centimeters) long—about the height of a bowling pin—and weighs around 0.1 pounds (44 grams), slightly lighter than the heaviest golf ball. In a recent Zootaxa paper, wildlife researchers Angus Emmott and Ross Coupland describe in stunning detail the new insect, which they found deep within the rainforests of the Atherton Tablelands, an elevated plateau in southeastern Australia that's about 3,000 feet (900 meters) high. A strange photograph of an unknown species sent to the pair prompted the researchers' trip to the Atherton Tablelands. Their outings typically transpired at night, when stick insects tend to be more active compared to the day, when they're at risk of predation from birds. After scouring the forests for hours on end with no luck, they finally managed to spot a lanky creature that matched the image in the mysterious photograph. Quietly, the researchers watched as the insect—which turned out to be female—laid eggs that looked nothing like anything they'd ever seen before. It was at this point that they became certain they were looking at an entirely new species of stick insect, Emmott recalled to the Australian Broadcasting Corporation (ABC). So far, scientists have only observed two female Acrohylla alta specimens, one from the researchers' outing and another found in a garden belonging to Emmott's friend. Based on these two discoveries, the researchers surmise that these supersized insects are exceptionally elusive, living in the highest canopies of high-altitude forests. 'Unless a bird knocks one down or you get a cyclone or a storm that knocks one down, we just can't find them up there in the canopy,' Emmott said. As for how they got so big, Emmott believes it may be on account of them living in a cool, wet environment. A larger body mass may have helped them to survive colder temperatures, he explained in a university statement. The new discovery illustrates how much we still don't know about these ancient rainforests, Peter Valentine, an environmental scientist at James Cook University who was not involved in the new work, told ABC. It's always exciting news when we discover new species, but at the same time it raises concerns about how well we're preserving rainforests, Valentine added. Emmott shares this sentiment. 'The scary thing is we may be losing species before we even know they exist,' he said. 'In the world of invertebrates, there is so much that we don't know yet and so many that are yet to be described.' In the meantime, Emmott says he'd like to find a male individual from the species, which would surely reveal even more about these extra-large critters.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store